International Biotechnology Trust


Rated Fund 2017-19. Provides diverse exposure to biotechnology companies

International Biotechnology is managed by a four-strong team at SV Life Sciences – Carl Harald Janson, Kate Bingham, Ailsa Craig and Marek Poszepcynski, whose backgrounds combine medical and/or scientific training, financial and commercial experience. This experience enables them to assess potential investment opportunities from a position of technical expertise and experience and consider which companies are the most likely to succeed.

The trust invests in both unquoted (usually earlier stage companies) as well as quoted equities. This broad spectrum of investments provides diversification while still giving exposure to potentially exciting returns.

The managers invest in companies with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology. They specialise in identifying the successful innovative drugs and medical devices that will serve unmet medical needs and which are in complex disease areas such as diabetes and cancer, as well as the most credible treatments for orphan diseases where the number of patients may be fewer but the path to approval may be smoother with less competition.

The type of companies they select provides investors with exposure to businesses at different stages of their development from early stage innovation, across regulatory hurdles, through to regulatory approval and revenue generation.

The trust predominantly aims to provide long-term capital growth but in 2016 introduced a dividend equivalent to 4% of net asset value, paid half yearly out of capital reserves. Its shares traded on a discount of as wide as 10% over the past year and 20% over three years, but at the end of 2018 they were trading at a small premium to underlying assets.

Narrative and ratings content all as of 01 January 2019.

See all Money Observer rated funds
International Biotechnology Trust
SV Life Sciences Managers LLP
Closed Ended Investment Company
Sector Specialist: Biotechnology & Healthcare
1.36 %
Risk Rating
3 Year Sharpe
3 Year Alpha
0 %
NASDAQ Biotechnology TR
Fund Size
£ 248.64 million
Discount Premium
The objective is to achieve long term capital growth by investing in high growth, development stage biotechnology companies that are either quoted or unquoted. The company invests in companies that are considered to be good value with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.
Holding %
Sv Fund Vi Investment 7.57 %
Celgene 6.23 %
Gilead Sciences Inc 5.56 %
Regeneron 4.12 %
Incyte 3.45 %
Acadia 3.35 %
Alexion Pharmaceuticals 3.06 %
Vertex Fund F Class 2.97 %
Stemline 2.68 %
Morphosys 2.59 %
SV Life Sciences Managers LLP
WB2B 6ST, London, United Kingdom
Legal Structure
Closed Ended Investment Company


Carl Harald Janson
Joined 09/02/2013
Ailsa Craig
Joined 03/01/2008
Kate Bingham
Joined 11/01/2000

Data provided by Morningstar.

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.